Adagloxad Simolenin

Summary

Adagloxad Simolenin (CHEMBL3707279) is a phase-3 clinical-stage unknown; indicated across 3 conditions including breast neoplasm and hepatocellular carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707279
Name	Adagloxad Simolenin
Type	Unknown
Max phase	3

Also known as: Adagloxad simolenin, OBI-822, OPT-822, ADAGLOXAD SIMOLENIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
breast neoplasm	3	MONDO:0021100	MONDO:0007254
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
ovarian cancer	2	MONDO:0008170	MONDO:0008170

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01516307	PHASE2	COMPLETED	Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
NCT02132988	PHASE2	UNKNOWN	Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer
NCT03608878	PHASE2	TERMINATED	Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).